✦ LIBER ✦

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

✍ Scribed by Noriyuki Koyama,Kenichi Saito,Yuki Nishioka,Wataru Yusa,Noboru Yamamoto…

Book ID: 126371269
Publisher: BioMed Central
Year: 2014
Tongue: English
Weight: 649 KB
Volume: 14
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-14-530

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase 1 dose-escalation study of the s

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

✍ Shapiro, Geoffrey I.; McCallum, Stewart; Adams, Laurel M.; Sherman, Laurie; Well 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 260 KB

Phase 1 dose-escalation study of oral ty

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

✍ J.C. Soria; C. Massard; N. Magné; Th. Bader; C.D. Mansfield; J.Y. Blay; B.N. Bui 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 288 KB

A phase I, first-in-human dose-escalatio

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB

A Phase I Dose-Escalation Study of Regor

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

✍ Mross, K.; Frost, A.; Steinbild, S.; Hedbom, S.; Buchert, M.; Fasol, U.; Unger, 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 392 KB

A phase 1 dose-escalation study of ARRY-

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

✍ Hanna Jean Khoury; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Maria 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB

Phase I, open-label, multicentre, dose-e

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

✍ Patrick Schöffski; Suzanne F. Jones; Herlinde Dumez; Jeffrey R. Infante; Elke Va 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 215 KB